Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of -137.55% is 571% below its 5-year average of 29.19%, around the middle of its 5-year range (-51852.61%–22445.96%).
98.68% above its 12-month average of -10434.97%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): -70.57%.
GROSS MARGIN
-137.55%
GROSS MARGIN AVG TTM
-10434.97%
GROSS MARGIN AVG 3Y
-130.82%
GROSS MARGIN AVG 5Y
29.19%
GROSS MARGIN AVG 10Y
26.14%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+98.68%
CURRENT VS 3Y AVG
-5.14%
CURRENT VS 5Y AVG
-571.25%
CURRENT VS 10Y AVG
-626.18%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
46.69%
median of 506 covered companies
CURRENT VS SECTOR MEDIAN
-394.60%
vs the sector median at left
Dare Bioscience, Inc.
Market Cap
$12.43M
Gross Margin
-137.55%
TTM Avg
-10434.97%
3Y Avg
-130.82%
5Y Avg
29.19%
Market Cap
$12.79M
Gross Margin
71.61%
TTM Avg
70.70%
3Y Avg
67.95%
5Y Avg
69.37%
Market Cap
$11.24M
Gross Margin
N/A
TTM Avg
-101.19%
3Y Avg
-33.23%
5Y Avg
-22.16%
Market Cap
$11.94M
Gross Margin
36.23%
TTM Avg
36.65%
3Y Avg
39.59%
5Y Avg
41.13%
Market Cap
$13.26M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$13.55M
Gross Margin
64.68%
TTM Avg
63.93%
3Y Avg
63.08%
5Y Avg
61.52%
Market Cap
$11.50M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Dare Bioscience, Inc. (DARE) | $12.43M | -137.55% | -10434.97% | -130.82% | 29.19% |
| Cytosorbents Corporation (CTSO)vs › | $12.79M | 71.61% | 70.70% | 67.95% | 69.37% |
| CytoMed Therapeutics Limited (GDTC)vs › | $11.24M | N/A | -101.19% | -33.23% | -22.16% |
| IRIDEX Corporation (IRIX)vs › | $11.94M | 36.23% | 36.65% | 39.59% | 41.13% |
| Cellectar Biosciences, Inc. (CLRB)vs › | $13.26M | 0.00% | 0.00% | 0.00% | 0.00% |
| Vyome Holdings, Inc. (HIND)vs › | $13.55M | 64.68% | 63.93% | 63.08% | 61.52% |
| IN8bio, Inc. (INAB)vs › | $13.62M | 0.00% | 0.00% | 0.00% | 0.00% |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $11.50M | 0.00% | 0.00% | 0.00% | 0.00% |
| Biofrontera Inc. (BFRI)vs › | $11.27M | 84.45% | 64.39% | 56.15% | 53.94% |
| Kiora Pharmaceuticals, Inc. (KPRX)vs › | $11.21M | 0.00% | 50.00% | 25.00% | -4489.78% |
Gross Margin
-137.6%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | -70.57% |
| 2026-03-31 | -422.76% |
| 2025-12-31 | 71.10% |
| 2025-09-30 | -51852.61% |
| 2025-06-30 | 100.00% |
| 2025-03-31 | -8935.20% |
| 2024-12-31 | 22445.96% |
| 2024-09-30 | 40.04% |
| 2024-06-30 | 100.00% |
| 2024-03-31 | -36034.10% |
| 2023-12-31 | -1092.72% |
| 2023-09-30 | 97.50% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 99.75% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 100.00% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 100.00% |
| 2017-03-31 | 100.00% |
| 2016-12-31 | 80.42% |
| 2016-09-30 | 0.00% |
| 2016-06-30 | 0.00% |
| 2016-03-31 | 0.00% |
| 2015-12-31 | 0.00% |
| 2015-09-30 | 0.00% |
| 2015-06-30 | 0.00% |
| 2015-03-31 | 0.00% |
| 2014-12-31 | 0.00% |
| 2014-09-30 | 0.00% |
| 2014-06-30 | 100.00% |
| 2014-03-31 | 100.00% |
| 2013-12-31 | 100.00% |
| 2013-09-30 | 0.00% |
| 2013-06-30 | 0.00% |
| 2013-03-31 | 0.00% |
